# Itacitinib for the Prevention of Graft Versus Host Disease

> **NCT04859946** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 31 (estimated)

## Conditions studied

- Hematologic and Lymphocytic Disorder

## Interventions

- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation
- **DRUG:** Busulfan
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Itacitinib
- **DRUG:** Tacrolimus
- **DRUG:** Thiotepa

## Key facts

- **NCT ID:** NCT04859946
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-01-11
- **Primary completion:** 2027-04-01
- **Final completion:** 2027-04-01
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04859946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04859946, "Itacitinib for the Prevention of Graft Versus Host Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04859946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*